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Summary.
The molecular conformation of the cardiac myosin motor is modulated by inter-molecular interactions among the heavy chain, the light chains, myosin binding protein-C (MyBP-C) and titin, and is governed by post-translational modifications (PTMs). In-gel digestion followed by liquid chromatography mass spectrometry (LC/MS/MS) has classically been applied to identify cardiac sarcomeric PTMs; however, this approach is limited by protein size, pI, and difficulties in peptide extraction. We report a solution-based workflow for global separation of endogenous cardiac sarcomeric proteins with a focus on the regulatory light chain (RLC) in which specific sites of phosphorylation have been unclear. Sub-cellular fractionation followed by OFFGEL electrophoresis (OGE) resulted in isolation of endogenous charge variants of sarcomeric proteins, including regulatory and essential light chains, myosin heavy chain (MHC), and MyBP-C of the thick filament. Further purification of RLC using reverse phase (RP) -HPLC separation and UV detection enriched for RLC PTMs at the intact protein level, and provided a stoichiometric and quantitative assessment of endogenous RLC charge variants. Digestion and subsequent LC/MS/MS unequivocally identified that the endogenous charge variants of cardiac RLC focused in unique OGE fractions were un-phosphorylated (78.8%), singly-(18.1%) and doubly-phosphorylated (3.1%) RLC. The novel aspects of this study are: 1) milligram amounts of endogenous cardiac sarcomeric sub-proteome were focused with resolution comparable to 2DE, 2) separation and quantification of post-translationally modified variants was achieved at the intact protein level, 3) separation of intact high molecular weight thick filament proteins was achieved in-solution, 4) endogenous charge variants of RLC were separated; a novel doublyphosphorylated form was identified in mouse, and singly-phosphorylated, singly-deamidated, and deamidated/phosphorylated forms were identified and quantified in human non-failing and failing heart samples, thus demonstrating the clinical utility of the method.
Introduction.
Modulation of sarcomeric protein function ensures that the heart ejects blood against a systemic resistance to supply peripheral tissues with oxygen and nutrients and removes carbon dioxide and wastes. Muscle contraction occurs by myosin motors of the thick filament reacting with actin and propelling thin filaments towards the center of the sarcomere. In cardiac muscle, contraction is activated by a release of sarcoplasmic reticular Ca 2+ that binds to troponin C, which is positioned on the actin thin filament. It was long assumed that regulation of Ca 2+ levels and cycling were the sole avenue by which contraction was modulated. It is now evident, however, that post-translational modifications (PTMs) are important in regulating the function of ejecting ventricles, as mechanisms downstream of Ca 2+ fluxes at the level of the sarcomere appear to dominate ejection and sustain ventricular elastance during systole (1) .
Intra-and inter-molecular interactions of sarcomeric thick and thin filament proteins are modifiable by PTMs, and it has been demonstrated that the intensity and dynamics of contraction and relaxation can be finely tuned via PTMs, particularly those of thin filament proteins (2, 3) . Mechanisms by which PTMs tune molecular interactions of the thick filament are less well understood. Extrapolating from molecular mechanisms to the cardiac disorder requires an understanding of the endogenous charge state of proteins which can be governed by phosphorylation, acetylation, oxidation and other post-translational modifications.
The thick filament is composed mainly of myosin, a motor protein that interacts with neighboring proteins, including the essential (ELC) and regulatory light chains (RLC), and myosin binding protein-C (MyBP-C) ( Figure 1 ). RLC binds the S1-S2 lever arm of the myosin motor and is optimally positioned at the fulcrum to modulate interactions between the globular MHC head, the coiled-coil LMM thick filament backbone and the neighboring MyBP-C ( Figure 1 ). Cardiac RLC is phosphorylated in large part by myosin light chain kinase (MLCK) (4) , which induces an increase in tension at sub-maximally activating levels of Ca 2+ (5-7) in skinned cardiac fibers bathed in exogenous MLCK. Furthermore, mice expressing a transgenic cardiac RLC housing alanine residues in place of N-terminal serines have significantly impaired systolic kinetics in vivo (8) . Separation of endogenous RLC by two-dimensional electrophoresis (2DE) clearly illustrates multiple phosphorylated spots of RLC (8) . The most abundant phosphorylated spot of RLC was found to represent phosphorylation at Ser-15 (9) . The second, more acidic phosphorylated spot is 3-5 times lower in abundance, and has been difficult to capture using ingel digestion and mass spectrometry, likely due to protein loss during in-gel digestion combined with poor ionization potential of the phospho-peptide. A possible approach to overcome this limitation is the use of a gel-free (in-solution) technique for separating charged species of RLC, designed to minimize loss and increase sample load.
Biochemically, proteins comprising the thick filament present unique purification challenges, in part, due to their large size (MHC, 223 kDa; MyBP-C, 150 kDa) producing difficulties in the isolation of intact proteins (10) (11) (12) collected not as part of a formal study design but rather to develop the biobank, which could be made available to investigators with an interest in the biology of human heart failure. Table I provides clinical details of the four samples used in the current study. A similar procurement strategy was employed for all specimens: at the time of explant, and following cardioplegia, a small portion of the left ventricle (<0.5 gm) was excised and promptly placed in liquid N 2 in the operating room and then subsequently stored at -70 0 for less than six months. Samples were shipped on dry ice from Denver to Chicago, and placed immediately at -70º C until the time of analysis.
Myofilament Enrichment and Sample Preparation. Sub-cellular fractionation proceeded according to methods previously described (16) All other criteria were set to software default settings. MS/MS spectra were first auto-validated with Spectrum Mill software, followed by manual inspection for confirmation of PTM identification. transitions from a total of 18 experiments (total of 72 transitions) and these values were discarded. The total area for each transition was combined between fractions for simplicity.
Targeted Analysis and Quantification of RLC Variants in DCM vs. Control by LC/MS/MS.

LC/MS/MS
Three experiments were conducted and the average and standard deviation were calculated. Ttests were used to determine if significant differences existed between isoforms from control and heart disease samples.
2DE.
Mouse myofilament sub-proteome was prepared according to sub-fractionation methods described above. Proteins were solubilized in IEF buffer, clarified with centrifugation (18,000 x g, 5 min, 25ºC), and labeled with Cy3. Proteins were separated over a non-linear, broad pI range 3-11 on 18 cm IPG strips according to methods previously described (8) . Strips were overlaid on 12% SDS-PAGE second dimension gels (18) for separation by molecular weight.
Gels were rinsed in water, and imaged using a Typhoon 9410 (GE Healthcare).
Results.
Preparation of Sarcomeric Sub-Proteome. Figure 2 shows the myofilament-enrichment using the Triton X-100 extraction method, originally described by Solaro et al. (16) 
RP-HPLC Separation Purifies Co-Focusing Sarcomeric Proteins in OGE.
To purify RLC charged species in each OGE fraction from co-migrating proteins, OGE fractions of interest were sequentially separated using RP-HPLC. Table II . RLC showed a striking 95% sequence coverage. The region of RLC not covered was the N-terminal MAPKKAK sequence due to the high lysine content. This high coverage demonstrates the power of using prefractionation and/or enrichment techniques in cases where detecting the majority of peptides is critical, as during PTM or isoform identification. Figure   5D unequivocally demonstrated that these two phosphorylations were on residues Ser-14 and Ser-15. This novel finding is the first report demonstrating a doubly-phosphorylated endogenous species of cardiac RLC. We have unequivocally identified three distinct charge species of RLC with high mass accuracy of both precursor and fragment ions inherent to the Q-TOF (see low mass errors in Figure 5 ). Importantly, RP-HPLC chromatograms of intact RLC protein detected with UV shown in Figure 4 demonstrate doubly-phosphorylated RLC as 3.1%, the singlyphosphorylated as 18.1%, and the un-phosphorylated as 78.8% of total sarcomeric RLC. It is also worthy to note that MS/MS spectra of un-, singly-, and doubly-phosphorylated peptides shown in Figure 5 have scored peak intensities (SPI %) between 92-96% and Spectrum Mill peptide scores between 19-21. The SPI % represents the percentage of the MS/MS peakdetected spectral ion current explained by the search interpretation, demonstrating the remarkably high confidence and fidelity of our MS/MS spectra. The peptide score reflects the information content in the MS/MS spectrum; a score of 13-25 is considered of excellent quality representing extensive peptide fragmentation, and when combined with SPI % of 70 or greater, the result is of high confidence and validity.
In-Solution Workflow Applied to Clinical Samples Reveals Significant Changes in RLC
PTMs in Human Heart Failure. To examine whether differential modifications are present in human heart failure, non-failing and failing dilated cardiomyopathy (DCM) samples were analyzed using the OGE-HPLC-MS/MS workflow. Human samples used were either "control" left ventricular tissue from donor hearts that were considered for heart transplantation or hearts from patients with dilated, non-ischemic cardiomyopathy explanted at the time of heart transplantation. Interestingly, human RLC was identified in OGE fractions 7, 8 and 9, whereas mouse RLC was identified in OGE fractions 5, 6 and 7. In silico alignment of human (Swiss Prot 869.4 +/-270.5) relative to non-failing controls, suggesting that the negative charge in the Nterminal region of RLC is reduced in human heart failure.
Discussion.
Effectiveness of a Rapid, In-Solution Method to Purify Endogenous Cardiac Proteins.
While 2DE is a powerful method for protein separation and resolution, when in preparation for analysis by mass spectrometry, in-gel approaches can be less than ideal. An inherent attribute of in-gel approaches is that proteins are encased inside a matrix and must be efficiently eluted for further analysis. Although protein digestion into smaller peptides should in theory cleave proteins into easily diffusible pieces, the reality is that losses incurred by this approach due to unavoidable incomplete digestion are still greater than if kept in solution. Additional limitations of 2DE include difficulties encountered in analysis of membrane proteins; extremely basic proteins which are resistant to focusing; and high molecular weight proteins that will not migrate into the first dimension IPG strip or from the IPG strip into the second dimension gel. We have taken advantage of a relatively new methodology, OGE (19) , and a classic biochemical method, RP-HPLC, and have applied these to cardiac proteins of the sarcomeric sub-proteome. With the era of "shotgun" proteomics steering the development of separation technologies, RP-HPLC of intact proteins has been widely underutilized despite the fact that analyzing proteins in their (25) . Following buffer optimization, they were able to enhance separation of myofilaments proteins and identify alterations in MHC in heart failure. into OFFGEL fractions with minimal overlap, thus providing an effective preparatory step for downstream PTM identification with mass spectrometry. Prior to using this approach, we had used 2DE to separate RLC charge variants followed by in-gel digestion and mass spec. While this approach was successful in identifying the highly abundant, singly-phosphorylated RLC species in rodent cardiac muscle (9), a doubly-phosphorylated peptide was undetectable with the mass spec. The current approach has proven to be more effective and will be of value for PTM identification of other sarcomeric proteins in future studies.
Advantages of OGE as a Preparatory Purification
Step of N-terminal RLC in rabbit cardiac muscle (44) , however our study is the first to map these modifications in human RLC, and to quantify the differences in human heart failure. The functional significance of the observed deamidation remains obscure, as this can be either a biologically relevant signal or a chemical artifact. Deamidation is a relatively common modification in human proteins, and has been generally thought of as a negative functional change via signaling proteins for degradation or replacement (45). It is surprising, therefore, that in our study the non-failing tissue shows significantly greater deamidation than the DCM samples. It is possible that cleavage of RLC at the residue 14/15 junction is occurring in DCM samples, as has been observed in human DCM (46) and rabbit ischemia-reperfusion (44), thus lowering the effective concentration of 9-30 peptide present in these samples. How the differences in each variant of RLC may contribute to the contractile dysfunction observed in heart failure is uncertain. It is unlikely that the observed decreases in RLC phosphorylation and deamidation are causative for heart failure, but rather the important finding reported here is that RLC is modified (along with other proteins) in a diseased state suggesting that this change may functionally contribute within the context of the pathogenesis of heart failure. -sensitizer with unknown mechanism, on skinned fibers from non-failing, idiopathic or ischemic cardiomyopathic patients, and reported significant increases in myosin-specific ATPase activity, independent of the thin filament regulatory proteins troponin and tropomyosin (52) . Additionally, our laboratory demonstrated that TG-RLC(P-) mice had altered in vivo systolic kinetics, measured by an increase in ejection time (8) reaction monitoring reveals differences in phosphorylation and deamidation. Heart tissue from non-failing and DCM patients was extracted and fractionated using OGE. Fractions (OGE-7, OGE-8, OGE-9) from 2 biological replicates were pooled and RLC species were separated via RP-HPLC as described above. Fractions were digested using Lys-C, and subjected to liquid chromatography tandem mass spectrometry using a triple quadrupole mass spectrometer. 9 product ion. Individual fractions were analyzed, the area determined for each transition, and the total area for each transition was combined between fractions for simplicity.
RLC in Therapeutic Interventions
Three experiments were conducted and the average and standard deviation were calculated and are shown. Transitions corresponding to the singly-phosphorylated and the phosphorylated/deamidated forms are significantly different between heart disease and control while singly-deamidated and unphosphorylated showed no difference. 
